Double-blind, randomized, parallel-group study on the efficacy and safety of oral granisetron and oral ondansetron in the prophylaxis of nausea and vomiting in patients receiving hyperfractionated total body irradiation

Bone Marrow Transplantation

Volumn 26, Issue 2, 2000, Pages 203-210

  Spitzer, T R ^a   Friedman, C J ^b   Bushnell, W ^b   Frankel, S R ^c   Raschko, J ^d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

^c UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Bone marrow transplant; Granisetron; Nausea; Ondansetron; Total body irradiation; Vomiting

Indexed keywords

ANTIEMETIC AGENT; GRANISETRON; ONDANSETRON;

ADULT; ARTICLE; ASTHENIA; BACKACHE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EDEMA; FEMALE; HEADACHE; HUMAN; INSOMNIA; MALE; NAUSEA; PARALLEL DESIGN; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RASH; VOMITING; WHOLE BODY RADIATION;

EID: 0033944505     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702479     Document Type: Article

References (34)

1. Basara N, Blau WI, Kiehl MG et al. Efficacy and safety of mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant recipient. Transplant Proc 1998; 30: 4087-4089.
2. Deeg HJ, Lin D, Leisenring W et al. Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial. Blood 1997; 89: 3880-3887.
3. von Bueltzingsloewen A, Bordigoni P, Witz F et al. Prophylactic use of ganciclovir for allogeneic bone marrow transplant recipients. Bone Marrow Transplant 1993; 12: 197-202.
4. Deeg HJ for the Seattle Marrow Transplant Team. Acute and delayed toxicities of total body irradiation. Int J Radiat Oncol Biol Phys 1983; 9: 1933-1939.
5. Alfieri AB, Cubeddu LX. Treatment with para-chlorophenylalanine antagonizes the emetic response and the serotonin-releasing actions of cisplatin in cancer patients. Br J Cancer 1995; 71: 629-632.
6. 3 receptors mediate cytotoxic drug and radiation-evoked emesis. Br J Cancer 1987; 56: 159-162.
7. Sanger GJ. The pharmacology of antiemetic agents. In: Andrews PLR, Sanger GJ (eds). Emesis in Anti-cancer Therapy: Mechanisms and Treatment. Chapman & Hall Medical: London, 1993, pp 179-210.
8. 3 receptor antagonists act as anti-emetics? In: Reynolds DJM, Andrews PLR, Davis CJ (eds). Serotonin and the Scientific Basis of Anti-Emetic Therapy. Oxford Clinical Communications: Oxford, 1995, pp 111-126.
9. 3 receptor antagonist efficacy in radiation-induced emesis. In: Reynolds DJM, Andrews PLR, Davis CJ (eds). Serotonin and the Scientific Basis of Anti-Emetic Therapy. Oxford Clinical Communications: Oxford, 1995, pp 134-141.
10. Aapro MS, Plezia PM, Alberts DS et al. Double-blind crossover study of the antiemetic efficacy of high-dose dexamethasone versus high-dose metoclopramide. J Clin Oncol 1984; 2; 466-471.
11. Hainsworth J, Harvey W, Pendergrass K et al. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. J Clin Oncol 1991; 9: 721-728.
12. 3 antagonist. Bone Marrow Transplant 1991; 7: 431-433.
13. Kris MG, Cubeddu LX, Gralla RJ et al. Are more antiemetic trials with a placebo necessary? Report of patient data from randomized trials of placebo antiemetics with cisplatin. Cancer 1996; 78: 2193-2198.
14. Kris MG, Gralla RJ, Clark RA et al. Antiemetic control and prevention of side-effects of anti-cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone: a double-blind, randomized trial. Cancer 1987; 60: 2816-2822.
15. Kris MG, Gralla RJ, Tyson LB et al. Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine: results of consecutive trials in 255 patients. Cancer 1985; 55: 527-534.
16. Kris MG, Tyson LB, Gralla RJ et al. Extrapyramidal reactions with high-dose metoclopramide (letter). New Engl J Med 1983; 309: 433-434.
17. Sridhar KS, Donnelly E. Combination antiemetics for cisplatin chemotherapy. Cancer 1988; 61: 1508-1517.
18. Bonneterre J, Chevallier B, Metz R et al. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy. J Clin Oncol 1990; 8: 1063-1069.
19. Latreille J, Pater J, Johnston D et al for the National Cancer Institute of Canada Clinical Trials Group. Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. J Clin Oncol 1998; 16: 1174-1178.
20. Marty M, Pouillart P, Scholl S et al. Comparison of the 5-hydroxytryptamine, (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. New Engl J Med 1990; 322: 816-821.
21. Navari RM, Kaplan HG, Gralla RJ et al. Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin. J Clin Oncol 1994; 12: 2204-2210.
22. Spitzer TR, Bryson JC, Cirenza E et al. Randomized double-blind, placebo-controlled evaluation of oral ondansetron in the prevention of nausea and vomiting associated with fractionated total body irradiation. J Clin Oncol 1994; 12: 2432-2438.
23. Gralla RJ, Itri LM, Pisko SE et al. Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. New Engl J Med 1981; 305: 905-909.
24. Malik IA, Khan WA, Qazilbash M et al. Clinical efficacy of lorazepam in prophylaxis of anticipatory, acute, and delayed nausea and vomiting induced by high doses of cisplatin. Am J Clin Oncol 1995; 18: 170-175.
25. Mercadante S. Nutrition in cancer patients. Supp Care Cancer 1996; 4: 10-20.
26. Abbott B, Ippoliti C, Bruton J et al. Antiemetic efficacy of granisetron plus dexamethasone in bone marrow transplant patients receiving chemotherapy and total body irradiation. Bone Marrow Transplant 1999; 23: 265-269.
27. Belkacémi Y, Ozsahin M, Pène F et al. Total body irradiation prior to bone marrow transplantation: efficacy and safety of granisetron in the prophylaxis and control of radiation-induced emesis. Int J Radiat Oncol Biol Phys 1996; 1: 77-82.
28. Dagher R, Robertson KA, Lucas KG et al. Outpatient total body irradiation for pediatric patients undergoing stem cell transplantation. Bone Marrow Transplant 1997; 19: 1065-1067.
29. Prentice HG, Cunningham S, Gandhi L et al. Granisetron in the prevention of irradiation-induced emesis. Bone Marrow Transplant 1995; 15: 445-448.
30. 3 receptor antagonist, for the prevention of radiation induced emesis during total body irradiation. Bone Marrow Transplant 1991; 7: 439-441.
31. Okamoto S, Takahashi S, Tanosaki R et al. Granisetron in the prevention of vomiting induced by conditioning for stem cell transplantation: a prospective randomized study. Bone Marrow Transplant 1996; 17: 679-683.
32. Stewart A, McQuade B, Cronje JDE et al on behalf of the Emesis Study Group for ondansetron and granisetron in breast cancer patients. Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in outpatients: a multicentre, double-blind, double-dummy, randomised, parallel-group study. Oncology 1995; 52: 202-210.
33. Pocock SJ. Problems with historical controls. In: Pocock SJ (ed). Clinical Trials: A Practical Approach. John Wiley: Chichester, 1995, pp 54-60.
34. Holdsworth MT. Ethical issues regarding study designs used in serotonin-antagonist drug development. Ann Pharmacother 1996; 30: 1182-1184.